Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid

Neuroscience

Volumn 78, Issue 4, 1997, Pages 967-975

  Miranda, A F ^a   Boegman, R J ^a   Beninger, R J ^a   Jhamandas, K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

dopamine; neuro protection; nicotinylalanine; NMDA; Parkinson's Disease; tyrosine hydroxylase

Indexed keywords

AMINO ACID RECEPTOR; AMPA RECEPTOR; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID; PROBENECID; QUINOLINIC ACID; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; CELL LOSS; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; ENZYME ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW; SUBSTANTIA NIGRA;

EID: 0030956088     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00655-0     Document Type: Article

References (41)

1. Areneda R. and Bustos G. (1989) Modulation of dendritic release of dopamine by N-methyl-D-aspartate receptors in rat substantia nigra. J. Neurochem. 52, 962-970.
2. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J. and Martin J. B. (1986) Replication of the neurochemical characteristics of Huntinton's disease by quinolinic acid. Nature 321, 168-171.
3. Beal M. F., Matson W. R., Swartz K. J., Gamache P. H. and Bird E. D. (1990) Kynurenine pathway measurements in Huntington's disease striatum:evidence for reduced formation of kynurenic acid. J. Neurochem. 55, 1327-1339.
4. Beninger R. J., Colten A. M., Ingles J. L., Jhamandas K. and Boegman R. J. (1994) Picolinic acid blocks the neurotoxic but not the neuroxexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunocytochemistry. Neuroscience 61, 603-612.
5. Bradford M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72, 248.
6. Carpenedo R., Chiarugi A., Russi P., Lombardi G., Carla V., Pellicciari R., Mattoli L. and Moroni F. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 612, 237-243.
7. Cockhill J., Jhamandas K., Boegman R. J. and Beninger R. J. (1992) Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cotrical cholinergic damage. Brain Res. 599, 57-63.
8. Connick J. H., Heywood G. C., Sills G. J., Thompson G. G., Brodie M. J. and Stone T. W. (1992) Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmac. 23, 235-239.
9. Connop B. P., Boegman R. J., Jhamandas K. and Beninger R. J. (1995) Excitotoxic action of NMDA agonists on nigrostriatal dopaminergic neurons: Modulaton by inhibition of nitric oxide synthesis. Brain Res. 676, 124-132.
10. Decker R. H., Brown R. R. and Price J. M. (1963) Studies on the biological activity of nicotinylalanine, an analogue of kynurenine. J. biol. Chem. 238, 1049-1053.
11. Di Loreto S., Florio T. and Scarnate E. (1992) Evidence that non-NMDA receptors are involved in the excitatory pathway from the pedunculopontine region to the nigrostriatal dopaminergic neurons. Expl Brain. Res. 89, 79-86.
12. Difazio M. C., Hollingsworth Z., Young A. B. and Penney J. B. (1992) Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology 42, 402-406.
13. Foster A. C., Collins J. F. and Schwarcz R. (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22, 1331-1342.
14. Foster A. C., Vezzani A., French E. D. and Schwarcz R. (1984) Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48, 273-278.
15. Foster A. C., Gill R. and Woodruff G. N. (1988) Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8, 4745-4754.
16. Foster A. C., Willis C. L. and Tridgett R. (1990) Protection against N-methyl-D-aspartate receptor mediated neuronal degeneration in rat brain by 7-chlorokynurenic acid and 3-amino-lhydroxypyrrolid-2-one, antagonists at the allosteric site for glycine. Eur. J. Neurosci. 2, 270-277.
17. Galli T., Godeheu G., Artaud F., Desce J. M., Pittaluga A., Barbeito L., Glowinski J. and Cheramy A. (1991) Specific role of N-acetyl-glutamate in the in vivo regulation of dopamine release from dendrites and nerve terminals of nigrostriatal dopaminergic neurons in the rat. Neuroscience 42, 19-28.
18. 3 H] kynurenine in the rat brain in vivo: Evidence for the existence of a functional kynurenine pathway. J. Neurochem. 65, 2621-2632.
19. Harris C. A., Boegman R. J., Jhamandas K. and Beninger R. J. (1993) Antagonism of quinolinic acid-induced toxicity on striatal diaphorase neurons following administration of kynurenine, probenecid and nicotinylalanine. Soc. Neurosci. Abstr. 19, 1345.
20. Hiller J. M., MacGarvey V. and Beal M. F. (1992) The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci. Lett. 1461, 115-118.
21. Hsu S. M., Raine L. and Fager H. (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. Am. J. clin. Path. 75, 734.
22. Kessler M., Terramani T., Lynch G. and Baudry M. (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J. Neurochem. 52, 1319-1328.
23. Kikuchi S. and Kim S. U. (1993) Glutamate neurotoxicity on mesencephalic dopaminergic neurons in culture. J. Neurosci. Res. 36, 558-569.
24. Kopin I. J. (1993) The pharmacology of Parkinson's disease therapy: an update. A. Rev. Pharmac. Toxicol. 33, 467-495.
25. McDonald J. W., Silverstein F. S. and Johnston M. V. (1988) Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res. 200, 200-203.
26. Merue G., Costa E., Armstrong D. M. and Vicini S. (1991) Glutamate receptor subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J. Neurosci. 11, 1359-1366.
27. Moroni F., Russi P., Gallo-Mezo M. A., Moneti G. and Pellicciari R. (1991) Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxin and nicotinylalanine. J. Neurochem. 57, 1630-1635.
28. Mount H., Quirion R., Kohn-Alexander J. and Boksa P. (1990) Subtypes of excitatory amino acid receptors involved in the stimulation of dopamine release from cell cultures of rat ventral mesecephalon. Synapse 5, 271-280.
29. Ogawa T., Matson W. R., Beal M. F., Myers R. H., Bird E. D., Milbury P. and Saso S. (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42, 1702-1706.
30. Perkins M. N. and Stone T. W. (1982) An iontophoretic investigation of the actions of the cunvulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184-187.
31. Roberts R. C., McCarthy K. E., Du F., Okuno E. and Schwarcz R. (1994) Immunocytochemical localization of the quinolinic acid synthesizing enzyme, 3-hydroxyanthranilic acid oxygenase, in the rat substantia nigra. Brain Res. 650, 229-238.
32. Russi P., Carla V. and Moroni F. (1989) Indolpyruvic acid administration increases the brain content of kynurenic acid. Biochem. Pharmac. 38, 2405-2409.
33. Russi P., Alesiani M., Lombardi G., Davolio P., Pellicciari R. and Moroni F. (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59, 2076-2080.
34. Schwarcz R., Whetsell W. O. Jr. and Mangano R. M. (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318.
35. Schwarcz R., Foster A. C., French E. D., Whetsell W. O. Jr. and Kohler C. (1984) Excitotoxic models for neurodegenerative disorders. Life Sci. 35, 19-32.
36. Schwarcz R., Du F., Schmidt W., Turski W. A., Gramsbergen J. B. P., Okuno E. and Roberts R. C. (1992) Kynurenic acid: A potential pathogen in brain disorders. Ann. N. Y. Acad. Sci. 648, 140-153.
37. Stone T. W. and Connick J. H. (1985) Quniolinic acid and other kynurenines in the central nervous system. Neuroscience 15, 597-617.
38. Vescei L., Miller J., MacGarvey V. and Beal M. F. (1992) Kynurenine and probenecid inhibit pentylenetetrazol- and NMDA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull. 282, 233-238.
39. Vrana S. L., Azzaro A. J. and Vrana K. E. (1992) Selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Molec. Pharmac. 41, 839-844.
40. Yamauchi T. and Fujisawa H. (1978) A simple and sensitive fluorometric assay for tyrosine hydroxylase. Analyt. Biochem. 89, 143-150.
41. Zeevalk G. D., Nicklas W. J. and Sonsalla P. K. (1994) NMDA receptor involvement in two animal models of Parkinson's disease. Neurobiol. Agng 15, 269-270.